Vladimir Simov

USPTO Granted Patents = 13 (Patent Applications = 2)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 12.1

ph-index = 6

Forward Citations = 90(Granted Patents)

Location History:

Boston, MA (US) (2017 - 2020)
South Boston, MA (US) (2016 - 2024)

Company Filing History:

13 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319671 - 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2025-06-03),

2. 12030872 - N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2024-07-09),

3. 11174248 - Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-16),

4. 11161854 - Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-02),

5. 10745364 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2020-08-18),

6. 10377768 - Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2019-08-13),

7. 10221146 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2019-03-05),

8. 10221142 - Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof (2019-03-05),

9. 9809561 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2017-11-07),

10. 9783511 - Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease (2017-10-10),

11. 9663502 - 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease (2017-05-30),

12. 9657033 - Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease (2017-05-23),

13. 9266827 - Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease (2016-02-23),

Sure, here is the article about inventor Vladimir Simov:

Title: Vladimir Simov: Pioneering Innovations in LRRK2 Inhibitors

Introduction:

Vladimir Simov, a talented inventor hailing from Boston, MA, has made significant contributions to the field of pharmaceuticals with his groundbreaking inventions. With a total of 11 patents under his belt, his work has been instrumental in the development of treatments for various diseases, particularly those involving the LRRK2 kinase.

Latest Patents:

Vladimir Simov's latest patents showcase his expertise in developing novel compounds as LRRK2 inhibitors. His inventions include Indazolyl-spiro[2.3]hexane-carbonitrile derivatives and Indazolyl-spiro[2.2]pentane-carbonitrile derivatives. These compounds have shown promising potential in treating diseases where LRRK2 kinase plays a crucial role, such as Parkinson's Disease.

Career Highlights:

Throughout his career, Vladimir Simov has worked with renowned companies in the pharmaceutical industry. He has made significant contributions during his time at Merck Sharp & Dohme Corporation and Lycera Corporation, where his innovative research has paved the way for groundbreaking pharmaceutical developments.

Collaborations:

In his pursuit of innovation, Vladimir Simov has collaborated with esteemed professionals in the field. Some of his notable coworkers include Kenneth Jay Barr and Blair T Lapointe, who have worked alongside him to propel forward the advancements in LRRK2 inhibitors and pharmaceutical compositions.

Conclusion:

Vladimir Simov's dedication to innovation and his pioneering work in developing LRRK2 inhibitors have earned him a well-deserved place among the leading inventors in the pharmaceutical industry. His patents and collaborations stand as a testament to his commitment to improving treatments for diseases, ultimately making a significant impact on the lives of many.

This text is generated by artificial intelligence and may not be accurate.